TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver

Sota Kato, Nagahiro Ochiai, Hiroki Takano, Fusayo Io, Noriko Takayama, Hiroko Koretsune, Ei-ichi Kunioka, Saeko Uchida, and Koji Yamamoto

Pharmacology Laboratories (S.K., N.O., F.I., N.T., H.K., E.-i.K., S.U., K.Y.) and Drug Safety and Pharmacokinetics Laboratories (H.T.), Taisho Pharmaceutical, Saitama, Japan

Received April 21, 2019; accepted October 2, 2019

ABSTRACT

Prolyl hydroxylase (PHD) 1/2/3 pan inhibitors are known to potentially induce erythropoietin (EPO) production in both the kidney and liver. The 2-[[1-[[6-(4-chlorophenoxy)pyridin-3-yl]methyl]-4-hydroxy-6-oxo-2,3-dihydropridine-5-carbonyl]amino]acetic acid (TP0463518) is a novel PHD 1/2/3 pan inhibitor; however, the main source of EPO production after TP0463518 administration remained to be investigated. We examined the effect of TP0463518 in inducing EPO production in the kidney and liver by measuring the hypoxia-inducible factor 2α (HIF-2α), EPO mRNA, and serum EPO levels in normal and bilaterally nephrectomized rats. Furthermore, we examined whether liver-derived EPO improved anemia in 5/6 nephrectomized (5/6 Nx) rats. TP0463518 scarcely increased the HIF-2α expression levels in the kidney cortex, whereas oral administration of TP0463518 at 20 mg/kg dramatically increased the HIF-2α expression level in the whole liver was 22-fold that in the whole kidney. In bilaterally nephrectomized rats, TP0463518 raised the hemoglobin level on day 14. The present study revealed that TP0463518 specifically induced EPO production in the liver and improved anemia. The characteristic feature of TP0463518 would lead to not only a more detailed understanding of the PHD–HIF2α–EPO pathway in erythropoiesis, but a new therapeutic alternative for renal anemia.

SIGNIFICANCE STATEMENT

Prolyl hydroxylase (PHD) 1/2/3 pan inhibitors are known to potentially induce erythropoietin (EPO) production in both the kidney and liver; however, their effects on renal EPO production have been shown to vary depending on the experimental conditions. The authors found that 2-[[1-[[6-(4-chlorophenoxy)pyridin-3-yl]methyl]-4-hydroxy-6-oxo-2,3-dihydropridine-5-carbonyl]amino]acetic acid (TP0463518), a PHD 1/2/3 pan inhibitor, specifically induced EPO production in the liver and that the liver-derived EPO was pharmacologically effective. Investigation of the effects of TP0463518 may pave the way for the development of a new therapeutic alternative for renal anemia patients.

Introduction

Erythropoietin (EPO) is a hematopoietic factor that acts on the EPO receptor to activate the Janus activating kinase 2 signaling cascade and stimulate the differentiation of erythroid progenitor cells into erythrocytes (Koury and Haase, 2015; Kuhrt and Wojchowski, 2015). In neonates and infants, EPO is mainly synthesized in the liver (Zanjani et al., 1981; Dame et al., 1998). During development, the main site of EPO production shifts from the fetal liver to the adult kidney (Rankin et al., 2007; Kapitsinou et al., 2010). The kidney thus becomes the main source of EPO in adults and is considered to be the most sensitive organ to hypoxia (Haase, 2017). Importantly, in nephropathy, renal EPO-producing cells transform to myofibroblasts and lose their EPO-producing capacity (Asada et al., 2011; Souma et al., 2013). As a result, patients with severe kidney diseases cannot produce sufficient EPO to maintain the hemoglobin level, and consequently develop renal anemia.

Expression of EPO is regulated by hypoxia-inducible factor (HIF)-2α, a master transcriptional regulator of the response to hypoxia. Under the normoxic condition, proline residues of HIF-2α are hydroxylated by HIF prolyl hydroxylase (PHD), which utilizes oxygen as a substrate (Hirsilä et al., 2003; Dao et al., 2009; Pappalardi et al., 2011). Hydroxylated HIF-2α is recognized by a ubiquitin ligase, von Hippel-Lindau protein, and degraded through the ubiquitin–proteasome pathway (Maxwell et al., 1999; Jaakkola et al., 2001). Under the hypoxic condition, the PHD activity is suppressed due to depletion of oxygen, and HIF-2α escapes hydroxylation and subsequent degradation. Stabilized HIF-2α binds to the hypoxia response element together with CREB-binding protein/p300 and the constitutively active HIFβ to upregulate EPO in both the

ABBREVIATIONS: 5/6 Nx, 5/6 nephrectomized; BNx, bilaterally nephrectomized; DMOG, dimethyloxaloylglycine; EPO, erythropoietin; HIF, hypoxia inducible factor; PHD, prolyl hydroxylase; SD, Sprague–Dawley; TP0463518, 2-[[1-[[6-(4-chlorophenoxy)pyridin-3-yl]methyl]-4-hydroxy-6-oxo-2,3-dihydropridine-5-carbonyl]amino]acetic acid.
kidney and liver (Haase, 2006). Three isoforms of PHD have been recognized, as follows: PHD1, PHD2, and PHD3. Genetically, deletion of the PHD2 gene alone increases the renal EPO production and hemoglobin levels (Takeda et al., 2008; Minamishima et al., 2009), and individuals with loss-of-function mutations in PHD2 show elevated blood hemoglobin levels (Percy et al., 2006, 2007; Ladroure et al., 2008). In contrast, triple knockout of PHD1/2/3 dramatically increases hepatic EPO expression (Minamishima and Kaelin, 2010; Tojo et al., 2015). Therefore, it is thought that PHD2 is involved in renal EPO production, whereas all the PHDs function cooperatively to regulate hepatic EPO expression.

Based on the finding that PHD inhibitors exert erythropoietic effects via inducing HIF-2α stabilization and EPO production, phase III trials of PHD inhibitors as alternative erythropoiesis-stimulating agents are underway. All the PHD inhibitors under clinical trials to date inhibit all three PHD isoforms and potentially induce EPO in both the kidney and liver (Flamme et al., 2014; Ariazi et al., 2017; Kato et al., 2018). However, the effects of the PHD inhibitors on the renal EPO production seem to vary depending on the type of PHD inhibitor used and the experimental conditions of nephropathy. When unilateral ureteral obstruction was induced in knockout mice lacking PHD1/2/3, myofibroblast-transformed renal EPO-producing cells proliferated in the damaged kidney and higher levels of EPO mRNA were found in the damaged kidney than in the healthy kidney (Souma et al., 2016). In contrast, the increase of the renal EPO mRNA expression induced by a PHD inhibitor was significantly lower in gentamicin-induced nephroptic rats as compared with healthy control rats, possibly due to the loss of the kidney parenchyma (Flamme et al., 2014). In contrast, the amount of liver-derived EPO induced by PHD inhibitors remains unchanged regardless of the stage of nephropathy. Therefore, we considered it important to conduct a detailed investigation of whether an inhibitor would act mainly on the kidney or on the liver.

The 2-[[1-[[6-(4-chlorophenoxy)pyridin-3-yl]methyl]-4-hydroxy-6-oxo-2,3-dihydropyridine-5-carbonyl]amino]acetic acid (TP0463518) is a competitive PHD1/2/3 pan inhibitor and increases the serum EPO levels in mice, rats, and monkeys (Kato et al., 2018). Because our previous study indicated that the serum EPO levels in 5/6 nephrectomized (5/6 Nx) Sprague–Dawley (SD) rats were comparable to those in healthy SD rats for the same plasma TP0463518 concentrations, we hypothesized that TP0463518 could increase hepatic EPO production without increasing EPO production in the kidney. In this study, we examined the production of EPO after administration of TP0463518 using healthy and bilaterally nephrectomized (BNx) rats, and also examined whether the liver-derived EPO improved the anemia in 5/6 Nx rats. Our study demonstrated that TP0463518 stabilized HIF-2α only in the liver and induced liver-derived EPO production, irrespective of the stage of nephropathy. Based on the present findings, we propose that TP0463518 could be developed as a new therapeutic alternative for patients with renal anemia.

Materials and Methods

**Compound.** TP0463518 was synthesized at Taisho Pharmaceutical, according to a previously described method (Hamada et al., 2018).

**Animal Protocol.** All animal protocols were approved by the Animal Committee of Taisho Pharmaceutical, and all the animal experiments were conducted under the approval of the committee. The room temperature and humidity were maintained at 23 ± 3°C and 50% ± 20%, respectively, with a light–dark cycle of 12/12 hours. Food and water were made freely available to the animals.

Seven-week-old SD rats (Japan SLC, Hamamatsu, Shizuoka, Japan) received oral TP0463518 administration. The rats were anesthetized, and blood samples were collected at each time point. Then the rats were euthanized, and the kidneys and liver were removed. The right kidney of the SD rats was divided into the inferior half and superior half. The inferior half (whole kidney) was cut into 3-mm-thick slices. All of the sliced whole kidney, specimens of the left kidney cortex, and specimens of the liver were immersed in RNAlater solution overnight at 4°C and then stored at −80°C until the mRNA extraction. The superior half of the right kidney and specimens of the liver were stored at −80°C to determine the organ TP0463518 exposure. Specimens of the left kidney cortex and of the liver were snap-frozen in liquid N2 and stored at −80°C until measurement of the organ levels of HIF-2α. The blood samples were mixed with EDTA. The samples were then centrifuged (4°C, 2130g, 10 minutes) to obtain plasma.

Bilateral nephrectomy was performed in 7-week-old SD rats under isoflurane and xylazine anesthesia. A midline incision was made, and the pedicle of the left kidney was ligated at two sites. The left kidney was removed by cutting between the two ligated sites. Then the right kidney was also removed in the same manner as the left kidney. The cecum and small intestine were returned to their original positions. Then, after suturing the fascia, the skin incision was closed with Aron Alpha. The rats were laid on a heat pad at 37°C during and after the surgery and observed until they regained consciousness. The sham rats were operated in the same way, except that the steps from ligation of the renal pedicle to removal of the kidneys were skipped. At 16 hours after the operation, the rats were administered TP0463518. In the first study, the BNx rats were euthanized at 4 hours after administration, and the kidneys (sham rats) and liver (sham and BNx rats) were removed to measure the EPO mRNA expression level. In the second study, blood was collected at 8 hours after administration from the subclavian vein under anesthesia. The samples were then centrifuged (room temperature, 2130g, 10 minutes) to obtain serum.

In the 5/6 Nx rats, two-thirds of the left kidneys of the SD rats were resected when the rats were 4 weeks old, and the right kidney was removed when the animals were 5 weeks old. As they became 10 weeks old, the 5/6 Nx rats were randomly assigned to the experimental groups, while ensuring that the variance and mean hemoglobin levels remained balanced among the groups. In the first study, the 5/6 Nx rats were euthanized at 2 hours after administration of TP0463518, and the remnant kidney and liver were removed. Specimens of the kidney cortex and liver were stored in RNAlater solution to measure the EPO mRNA. In the second study, the 5/6 Nx rats received oral vehicle or TP0463518 administration once daily for 14 days. Blood was collected from the tail vein on days 0, 7, and 14. The blood samples were mixed with EDTA and analyzed using ADVIA 120 (Siemens Healthcare Diagnostics, Tokyo, Japan).

**Cellular Assay.** HepG2 and H4-II-E-C3 carcinoma cell lines were seeded in 48-well plate at 2.0 × 10⁴ cells/well or 1.2 × 10⁵ cells/well, respectively, in Dulbecco’s modified Eagle’s medium (GIBCO) supplemented with 10% fetal bovine serum (GIBCO). Twenty-four hours after seeding, the medium was changed to 100 µl opti-MEM (GIBCO) containing various concentrations of TP0463518. The cells were incubated for 24 hours, and then the mRNA was extracted to measure EPO mRNA expression. Another plate of cells was incubated for 72 hours, and then the media were collected to measure EPO concentration in the media.

**Measurement of EPO mRNA.** The mRNA in the cells, renal cortex, and liver was extracted using RNaseasy Plus Mini Kit (Qiagen), according to the manufacturer’s manual. The mRNA from the whole kidney was prepared as follows. The inferior half of the right kidney...
was homogenized with Tissue Lyser in 1200 μl buffer RLT. Then, 150 μl homogenate was added to 500 μl buffer RLT. The remaining steps were carried out according to the manual. Reverse-transcription and real-time quantitative polymerase chain reaction were carried out according to the standard methods (Tea et al., 2009; Wigeland et al., 2011). The primer sequences are listed in Table 1. In the case of EPO expression below the detection limit (three cases in liver in all the experiments), the EPO expression was calculated by substituting 40 for the cycle threshold value.

Relative EPO mRNA expressions in the cells, renal cortex, and liver were calculated as the ratios to those in the vehicle group. The total EPO mRNA expressions were calculated using a modification of the method described by Eckardt et al. (1992). The total EPO mRNA expressions were calculated as shown in eq. 1.

$$\text{Total EPO mRNA expression} = \frac{\text{total EPO mRNA expression}}{\text{organ weight} \times \text{organ weight}}$$

(1)

For EPO mRNA/hypoxanthine–guanine phosphoribosyltransferase mRNA and organ weight, measured values were substituted. For RNA amount/organ weight, the values were cited from the previous study (Eckardt et al., 1992). Our preliminary data indicated that the hypoxanthine–guanine phosphoribosyltransferase mRNA/RNA amount was almost the same between the kidney and liver, as reported previously (Vandesompele et al., 2002). Therefore, eq. 1 could be converted to eq. 2, as follows, where $k$ is a constant, such that the total EPO mRNA expression in the kidney is 1.

$$\text{Total EPO mRNA expression} = \frac{\text{EPO mRNA expression}}{\text{organ weight} \times \text{organ weight}}$$

(2)

**Determination of HIF-2α Expression in the Kidney Cortex and Liver.** The kidney cortices and livers were homogenized in 10 volumes of protein extraction buffer (20 mM Tris-HCl, pH 8.0, 1.5 mM MgCl$_2$, 420 mM NaCl, 25 vol% glycerol, 0.2 mM EDTA, 0.5 vol % IGEAL CA-630, 1 mM diithiothreitol, 1 mM phenylmethylsulfonyl fluoride, and proteinase inhibitor cocktail), and the homogenates were centrifuged (4°C, 15,000 g, 10 minutes) to prepare the protein extracts. The extracts were mixed with sample buffer and heated at 96°C for 5 minutes. Then 140 μg protein extracts were applied to SDS-PAGE. The gels were stained with Coomassie Brilliant Blue, and an area of 90–120 KDa was cut out and dried. Cysteine residues in the protein of the gel were reduced at 56°C for 80 minutes with reduction buffer (10 mM diithiothreitol and 25 mM ammonium bicarbonate) and then alkylated at room temperature for 45 minutes, protected from light, with alkylation buffer (55 mM iodoacetamide and 25 mM ammonium bicarbonate). Then the gels were dried again, and the proteins in the gels were digested with 200 ng/ml trypsin at 37°C for 15 hours. After the digestion, peptides were extracted from the gels with extraction buffer (50% acetonitrile and 1% formic acid). Stable isotope-labeled peptides (GQVVS(Gly$_{12}$C$_{2}$)$_{12}$N)$_{2}$)QYR and LAISF(Leu$_{12}$C$_{2}$)$_{12}$N(R) were added to the peptide extracts as an external standard. The peptide extracts were separated with DiNa nano-LC system (KYA Technologies, Tokyo, Japan) and analyzed with QTRAP 5500 (AB Sciex LLC, Framingham, MA). A standard curve was prepared with unlabeled peptides.

**Determination of EPO in Serum and Medium.** The EPO levels in serum and medium were measured using a commercially available EPO ELISA kit (rat, BioLegend, San Diego, CA; human, Stemcell Technologies, Vancouver, Canada), according to the manufacturer’s manual. EPO levels below the detection limits were considered as zero for the purpose of analysis.

**Determination of the TP0463518 Concentration in the Kidney, Liver, and Plasma.** The TP0463518 concentrations in the kidney, liver, and plasma were measured by liquid chromatography–tandem mass spectrometry, using the LC-20AD high-pressure liquid chromatography system (Shimadzu, Kyoto, Japan) and API4000 (AB Sciex LLC).

**Statistics.** Data are shown as the means ± S.E.M. or means ± S.D. As the EPO mRNA expression levels increased exponentially, the means and S.E.M. were calculated for logarithmically transformed values of EPO mRNA. The statistical significances of differences were determined using the Student’s t test or Dunnett’s test, using SAS 9.2. Statistical significance was defined as $P < 0.05$.

### Results

**TP0463518 Only Slightly Increases Renal EPO Production in Healthy Rats.** To examine whether TP0463518 exerts EPO-producing effect in the kidney, we addressed the effect of TP0463518 on the HIF-2α and EPO mRNA expression levels in the kidney cortex after administration of 20 mg/kg TP0463518. TP0463518 failed to increase the HIF-2α level in the kidney cortex for 24 hours (Fig. 1A). The EPO mRNA expression in the kidney cortex increased slightly at 2 and 4 hours after the TP0463518 administration and returned to the baseline level thereafter (Fig. 1B). Analysis of the dose dependence of the effect of TP0463518 on the HIF-2α and EPO mRNA expressions at 4 hours showed that TP0463518 did not change the HIF-2α levels up to 40 mg/kg (Fig. 1C). TP0463518 did not change the EPO mRNA levels up to 10 mg/kg, except thereafter, slightly, but significantly increased the EPO mRNA expression level at 20 mg/kg or more (Fig. 1D). These results indicated that TP0463518 only slightly induced EPO mRNA expression in the kidney cortex, but this effect was transient and HIF2α-independent.

We also addressed the effect of dimethyloxaloylglycine (DMOG), another PHD inhibitor, on the EPO mRNA expression in the kidney cortex at 4 hours after administration of 60 and 600 mg/kg. The EPO mRNA levels did not change at 60 mg/kg DMOG, but slightly increased at 600 mg/kg (Supplemental Fig. 1A).

**TP0463518 Increases Hepatic EPO Production in Healthy Rats.** We next measured the HIF-2α and EPO mRNA expression levels in the liver to examine whether TP0463518 exerts EPO-producing effect in the liver. HIF2α markedly increased in the liver at 1 hour after TP0463518 administration and peaked at 2 hours (Fig. 2A). At 2 hours postadministration, TP0463518 significantly increased liver HIF2α at 5 mg/kg or more in a dose-dependent manner; the increase in HIF-2α expression at 40 mg/kg TP0463518 was 5.7-fold higher from 0.27 fmol/mg in the vehicle-treated group to 1.53 fmol/mg in the 40 mg/kg TP0463518-treated group (Fig. 2C). Remarkably, the EPO mRNA expression level

### Table 1

<table>
<thead>
<tr>
<th>Gene</th>
<th>Sequence (5' to 3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human</td>
<td>18S</td>
</tr>
<tr>
<td></td>
<td>GGAACCGGCGGATGAGAGGC</td>
</tr>
<tr>
<td></td>
<td>GATACCACTGCTGTTCTTCC</td>
</tr>
<tr>
<td></td>
<td>GGTCGCCCTGCCATCTCCTC</td>
</tr>
<tr>
<td></td>
<td>GACCGCTGCTGCTTCTTCC</td>
</tr>
<tr>
<td>Rat</td>
<td>HPRT</td>
</tr>
<tr>
<td></td>
<td>GTTTGAGATAATTCCCTGACT</td>
</tr>
<tr>
<td></td>
<td>CCGCTGCTTTTTGCTGTTG</td>
</tr>
<tr>
<td></td>
<td>ACCCGAGCTTCCACGCTTC</td>
</tr>
<tr>
<td></td>
<td>GAGGGCCATCATGATCTTTC</td>
</tr>
</tbody>
</table>

18S, 18s rRNA; HPRT, hypoxanthine guanine phosphoribosyltransferase.
increased dramatically following administration of TP0463518 and remained high for over 24 hours, with the peak at 4 hours post-TP0463518 administration (Fig. 2B). At 4 hours post-administration, the increase of the EPO mRNA level induced by TP0463518 was dose-dependent, and the expression level in the 40 mg/kg TP0463518-treated group was 1300-fold higher than that in the vehicle-treated group (Fig. 2D). DMOG dose-dependently increased EPO mRNA levels in the liver at 4 hours postadministration (Supplemental Fig. 1B). The increase of EPO mRNA was 7800-fold higher in the 600 mg/kg DMOG-treated group than that in the vehicle-treated group.

**Total EPO mRNA Expression Levels in the Whole Liver Are Higher Than Those in the Whole Kidney.** Because EPO mRNA expression in the adult rat liver is very low (Eckardt et al., 1992; Tan et al., 1992), the marked increase in the relative EPO mRNA expression level could be a result of overestimation of the mRNA levels after TP0463518 administration. We therefore estimated the total EPO mRNA expression levels in the whole liver and whole kidney by multiplying EPO mRNA levels in the liver and kidney by the organ weight and total mRNA expression amount in each organ. The total EPO mRNA expressions in each organ after TP0463518 administration were then compared in reference to the renal EPO mRNA level in the vehicle-treated group set as 1 (see Materials and Methods). In the kidney, the total EPO mRNA expression level failed to increase up to 10 mg/kg TP0463518, and then slightly increased at doses of 20 and 40 mg/kg (Fig. 3). In the vehicle-treated group, the total EPO mRNA expression level in the whole liver was 0.29-fold to that in the whole kidney. Importantly, this expression became 18-fold higher in the group treated with 10 mg/kg TP0463518. Furthermore, at 20 mg/kg TP0463518, the total EPO mRNA in the whole liver was 22-fold higher than that in the whole kidney, even though the total EPO mRNA expression in the whole kidney was slightly increased under this condition. These results explicitly demonstrated that TP0463518 was considerably more potent at inducing EPO production in the liver than in the kidney.

In the 600 mg/kg DMOG-treated group, the total EPO mRNA expression levels in the whole liver were 79-fold higher than that in the whole kidney (Supplemental Fig. 2). **TP0463518 Increases the Serum EPO Levels in BNx Rats.** We next examined whether the rise in the serum EPO levels after TP0463518 administration could reflect the increased EPO mRNA expression levels in the liver. We previously reported that TP0463518 increased the serum EPO levels in 5/6 Nx rats (Kato et al., 2018). However, because 5/6 Nx rats have a remnant kidney, we could not exclude the effect of TP463518 on the remaining kidney in the rise of the serum EPO levels. Therefore, we examined the EPO-producing effect of TP0463518 in BNx rats. TP0463518 at 10 and 20 mg/kg did not increase the EPO mRNA expression in the kidney in the sham rats (Fig. 4A), indicating that the kidney did not contribute to the rise of the serum EPO levels after TP0463518 administration in the sham rats. TP0463518 at the doses of 10 and 20 mg/kg increased the EPO mRNA expression levels in the liver of the sham rats by 56- and 388-fold, respectively (Fig. 4B).
TP0463518 at the same doses also raised the EPO mRNA expression levels in the livers of the BNx rats by 127- and 753-fold, respectively, indicating that TP0463518 induces EPO mRNA expression increase in the liver even in BNx rats.

The serum EPO concentration in the BNx rats was below the detection limit at 24 hours after nephrectomy (Fig. 4C) because BNx rats do not have EPO secretion from the kidney. In normal rats, TP0463518 increased the serum EPO concentration in a dose-dependent manner, as previously reported (Kato et al., 2018). In the sham rats, TP0463518 increased the serum EPO concentrations from 18 pg/ml in the vehicle-treated group to 71 pg/ml in the 20 mg/kg TP0463518-treated group. In the BNx rats, TP0463518 at 10 and 20 mg/kg also raised the serum EPO concentrations from 0 (below detection limit) to 28 and 180 pg/ml, respectively. Therefore, consistent with the effective increase in the hepatic EPO mRNA levels induced by TP0463518 administration, the serum EPO concentrations were higher in the BNx rats than in the sham rats. These results demonstrated that TP0463518 induced hepatic EPO production and, in turn, increased liver-derived EPO concentrations in the serum.

**TP0463518 Has a Higher EPO-Inducing Potency in the Liver Than in the Kidney.** To investigate whether the differential actions of TP0463518 on EPO expression between the liver and kidney are attributable to the difference in the exposure levels of TP0463518 between these organs, we measured the TP0463518 concentrations in each of these organs. In healthy rats, the TP0463518 concentrations at 4 hours postadministration were 5.3–6.4 and 17.5–23.5 times higher in the kidney and the liver compared with plasma, respectively (Table 2). To investigate the relationship between the TP0463518 concentrations and EPO mRNA expression levels, we plotted the EPO mRNA levels against the corresponding TP0463518 concentrations in the kidneys and liver. EPO mRNA expression in the liver increased in an exposure-dependent manner (Fig. 5). In contrast, the EPO mRNA expression level in the kidney scarcely increased despite the increase of the TP0463518 concentration. At the same TP0463518 concentrations that yielded 5940 ng/g in the liver (10 mg/kg) and 5910 ng/g in the kidney (40 mg/kg), the EPO mRNA expressions increased by 185-fold and 3.0-fold, respectively. These results demonstrated that TP0463518 exerted its EPO-producing effect almost exclusively in the liver and greatly contributed to augmentation of EPO levels in the serum.

**Liver-Derived EPO Ameliorates Anemia.** We next addressed whether liver-derived EPO induced by TP0463518 has ameliorating effects on anemia; we administrated TP0463518 to 5/6 Nx rats, which is a model of renal anemia. Although a single administration of TP0463518 at 10 or 20 mg/kg to 5/6 Nx rats failed to increase the renal EPO mRNA expression, it markedly increased the hepatic EPO mRNA expression by 670- and 1800-fold, respectively, as compared with the level in the vehicle-treated group (Fig. 6). Therefore, in 5/6 Nx rats, in which most of the kidney tissue has been removed, TP0463518 was not effective in inducing
TP0463518 increases EPO mRNA expression exclusively in the liver. Scatter plot of EPO mRNA expression levels against the TP0463518 concentrations. Individual EPO mRNA expression levels in the liver and kidney are plotted against the corresponding plasma TP0463518 concentrations (n = 24 in each organ). The EPO mRNA expression levels in the vehicle-treated group are plotted on the left (n = 6 in each organ). Although EPO mRNA expression in the liver increased in an exposure-dependent manner, the EPO mRNA expression level in the kidney scarcely increased despite the increase of the TP0463518 concentration. Open circles; kidney; filled circles; liver.

**TABLE 2**

TP0463518 concentrations in the plasma, liver, and kidney at 4 hours after administration (ng/mg plasma or g tissue)

<table>
<thead>
<tr>
<th>Matrix</th>
<th>5 mg/kg</th>
<th>10 mg/kg</th>
<th>20 mg/kg</th>
<th>40 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma</td>
<td>166 ± 53.4</td>
<td>337 ± 120</td>
<td>669 ± 160</td>
<td>1130 ± 357</td>
</tr>
<tr>
<td>Liver</td>
<td>3810 ± 1090</td>
<td>5940 ± 1330</td>
<td>11,700 ± 1120</td>
<td>20,300 ± 2970</td>
</tr>
<tr>
<td>Kidney</td>
<td>1040 ± 324</td>
<td>2040 ± 790</td>
<td>3810 ± 1330</td>
<td>5930 ± 1690</td>
</tr>
<tr>
<td>Ratio (L/P)</td>
<td>23.5 ± 5.3</td>
<td>18.8 ± 5.9</td>
<td>18.1 ± 3.5</td>
<td>17.5 ± 2.8</td>
</tr>
<tr>
<td>Ratio (K/P)</td>
<td>6.4 ± 0.6</td>
<td>6.0 ± 0.7</td>
<td>5.7 ± 0.8</td>
<td>5.3 ± 0.4</td>
</tr>
</tbody>
</table>

renal EPO production up to 20 mg/kg, unlike in normal rats.

In the 5/6Nx rats, although the reticulocyte count was similar to that in the sham rats (263 ± 8 vs. 255 ± 12 billion cells/l), the hemoglobin concentration was significantly lower than that in the sham rats (15.8 ± 0.1 vs. 13.4 ± 0.3 g/dl), indicating that the 5/6 Nx rats had anemia. After once-daily administration of TP0463518 for a week to these rats, the reticulocyte count increased in a dose-dependent manner, and the count was 481 ± 23 billion cells/l at 10 mg/kg (Fig. 7A). The hemoglobin concentration in the vehicle-treated group was still low as compared with that in the sham rats after 2 weeks of repeated administration (16.6 ± 0.2 vs. 14.2 ± 0.4 g/dl). However, the hemoglobin concentration in the TP0463518-treated groups increased in a dose-dependent manner, and the concentration reached 16.8 ± 0.4 g/dl at 10 mg/kg TP0463518, which was comparable to the hemoglobin concentration in the sham rats (Fig. 7B). The hematocrit increased from 41.4 ± 1.2 in the vehicle-treated group to 51.4 ± 1.2% at 10 mg/kg, becoming comparable to that in the sham rats (49.1% ± 0.7%) (Fig. 7C). The red blood cell count also increased from 7.40 ± 0.24 to 8.80 ± 0.20 million cells/μl (9.09 ± 0.14 million cells/μl in the sham rats; Fig. 7D).

**TP0463518 Increases EPO Expression in Human and Rat Cell Lines.** To examine whether TP0463518 exerts EPO-producing effect in the liver cells, we addressed the effect of TP0463518 on EPO mRNA expression and EPO secretion in the human and rat liver cell lines, HepG2 and H4-II-E-C3. After the treatment of the cells with TP0463518 for 24 hours, EPO mRNA levels in both HepG2 and H4-II-E-C3 cells increased at 10 μM or more; the increase at 30 μM was 4.04- and 3.47-fold higher than control group, respectively (Fig. 8, A and B). EPO concentration in the medium of HepG2 cells treated with TP0463518 for 72 hours increased from 38.7 mU/ml in control wells to 74.0 mU/ml at 30 μM (Fig. 8C). EPO concentration in medium of H4-II-E-C3 cells treated with TP0463518 for 72 hours also increased from 79.1 pg/ml in control wells to 254.9 pg/ml at 30 μM (Fig. 8D). These results indicated that TP0463518 increased EPO expression not only in rat liver but also in human liver.

**Discussion**

TP0463518 is a PHD1/2/3 pan inhibitor and now under phase 1 clinical trials for renal anemia (Kato et al., 2018; Shinfuku et al., 2018). Based on previous findings, in this study, we investigated whether TP0463518 specifically induced EPO production in the liver. This study indicated that whereas TP0463518 did not induce HIF-2α–dependent EPO mRNA expression in the kidney, it markedly induced HIF-2α and EPO mRNA expression in the liver. The different action of TP0463518 could not be ascribed to different TP0463518 concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA concentrations between the kidney and liver. Consistent with the findings that TP0463518 increased hepatic EPO mRNA expression, the serum EPO concentrations in BNx rats increased to an extent comparable to or more than that in the sham rats. Furthermore, TP0463518 induced EPO mRNA.
expression only in the liver in 5/6 Nx rats. These results thus clearly demonstrate that TP0463518 enhanced EPO production much more potent in the liver and increased the serum concentrations of EPO. We further demonstrated that liver-derived EPO induced by TP0463518 was pharmacologically effective in ameliorating nephrectomy-induced anemia. Repeated administration of TP0463518 at 20 mg/kg, although not increasing the renal EPO mRNA expression, greatly improved the hemoglobin levels in the 5/6 Nx rats to the same degree or more than that in the sham rats in a dose-dependent manner. Therefore, TP0463518 is a liver-specific PHD inhibitor at a therapeutic dose and has the potent ability to induce sufficient hepatic EPO production to ameliorate anemia. Additionally, TP0463518 increased EPO expression in human and rat cell lines, HepG2 and H4-II-E-C3. These results indicated that TP0463518 increased EPO expression not only in rat liver but also in human liver.

A number of studies have to date investigated the effects of genetic or pharmacological PHD suppression in animal models of nephropathy (Flamme et al., 2014; Souma et al., 2016). When unilateral ureteral obstruction was induced in knockout mice lacking PHD1/2/3, the EPO mRNA levels in the damaged kidney were higher than those in the healthy kidney (Souma et al., 2016). In contrast to these findings, the increase in renal EPO mRNA expression induced by a PHD inhibitor was significantly lower in gentamicin-induced nephropathic rats as compared with healthy control rats (Flamme et al., 2014). These findings suggest that the effects of a PHD inhibitor on the renal EPO production vary depending on the stage of nephropathy. Interestingly, hepatic EPO expression induced by a PHD inhibitor was reportedly almost comparable between gentamicin-induced nephropathic rats and healthy control rats (Flamme et al., 2014). These findings suggest that the effects of a PHD inhibitor on the renal EPO production vary depending on the stage of nephropathy. Interestingly, hepatic EPO expression induced by a PHD inhibitor was reportedly almost comparable between gentamicin-induced nephropathic rats and healthy control rats (Flamme et al., 2014). There is no explicit evidence until date indicating that PHD inhibitors have the ability to stabilize HIF-2α specifically in the liver and increase liver-derived serum EPO concentrations. FG-2216 increased the serum EPO levels in anephric hemodialysis patients, but the increase of the serum EPO was smaller than that in nephric hemodialysis patients (Bernhardt et al., 2010). Molidustat was reported to increase the renal EPO mRNA expression in rats by several hundred fold, but raised hepatic EPO mRNA expression by only several 10 times (Flamme et al., 2014). Three other PHD inhibitors are now under phase 3 clinical trials (Coyne et al., 2017), but the main organ source of EPO production after administration of these inhibitors remains
unknown. Therefore, to the best of our knowledge, TP0463518 is the only clinical compound inducing EPO specifically in the liver to ameliorate anemia.

TP0463518 scarcely induced EPO production in the kidney cortex despite the increase of the TP0463518 concentration. As kidney is a highly heterogeneous organ, the localization of the compound should be considered. The urinary excretion rates of FG-2216 and molidustat, which induced renal EPO, were 11% and 1.4%–3.6%, respectively (Bernhardt et al., 2010; Böttcher et al., 2018). In contrast, the urinary excretion rate of TP0463518 was almost zero, and DMOG, which dominantly induced hepatic EPO, was metabolized in the liver (Hamada et al., 2018; Singh et al., 2019). Taking these points into consideration, a compound in the tubular might be delivered to the tubulo-interstitium, and then the compound would exert EPO-producing effect in the kidney.

It is also noteworthy that liver-specific PHD1/2/3 triple-knockout mice reportedly increased hepatic EPO expression and developed polycythemia (Minamishima and Kaelin, 2010; Tojo et al., 2015). Furthermore, liver-derived EPO was also reported to cause polycythemia in specific liver-vincent with Hoppel-Lindau protein knockout mice (Haase et al., 2001; Rankin et al., 2007). Higher hepoglobin level is associated with increased risk of stroke, cardiovascular events, and dialysis (Driuèke et al., 2006; Singh et al., 2006; Pfeffer et al., 2009). Therefore, it is crucial to ameliorate anemia without causing polycythemia.

TP0463518 increased hepoglobin levels in the correction phase with a clear dose response from 2.5 mg/kg, at which TP0463518 was ineffective, to 20 mg/kg, at which TP0463518 was excessive. This result suggests that an adequate dose adjustment of TP0463518 could control hemoglobin levels within desirable range in the maintenance phase. TP0463518 is now being examined in a clinical trial, and the clinical proof of concept will be available in the future.

The present study thus revealed a very unique feature of TP0463518, in that TP0463518 stabilized HIF-2α and induced EPO specifically in the liver at a therapeutic dose. Furthermore, TP0463518 improved the hepoglobin level to within normal range with a good dose response, and was expected to allow hemoglobin levels to be maintained in the normal range over the long term without causing polycythemia. Therefore, the characteristic feature of TP0463518 would lead to not only a more detailed understanding of the PHD–HIF2–EPO pathway in erythropoiesis, but also a new therapeutic alternative for renal anemia in patients with chronic kidney disease.

Acknowledgments

We thank Dr. Shigetada Nakanishi, Dr. Yoshiki Fukasawa, and Dr. Shigetaka Chaki for valuable suggestions during the preparation of this manuscript, and Chie Koizumi, Yosuke Nakamura, and Tore Eriksson for technical support.

Authorship Contributions

Participated in research design: Kato, Kunioka, Uchida.
Conducted experiments: Kato, Ochiai, Takano, Io, Takayama, Kojunetsu, Kunioka.
Performed data analysis: Kato, Ochiai.
Wrote or contributed to the writing of the manuscript: Kato, Takano, Yamamoto.

References


